SHAKE WELL BEFORE USING. Two drops topically in the eye(s) four times daily. In cases of bacterial infections, concomitant use of anti-infective agents is mandatory. Care should be taken not to discontinue therapy prematurely. If signs and symptoms fail to improve after two days, the patient should be re-evaluated (SEE PRECAUTIONS).
The dosing of OMNIPRED® suspension may be reduced, but care should be taken not to discontinue therapy prematurely.
In chronic conditions, withdrawal of treatment should be carried out by gradually decreasing the frequency of applications.
OMNIPRED® (prednisolone acetate ophthalmic suspension) is supplied in a white, round low density polyethylene DROP-TAINER® dispenser with a natural low density polyethylene dispensing plug and pink polypropylene cap. Tamper evidence is provided with a shrink band around the closure and neck area of the package.
5 mL NDC 0065-0638-27
10 mL NDC 0065-0638-25
STORAGE: STORE at 8° — 24°C (46° — 75°F) in an UPRIGHT position.
ALCON LABORATORIES, INC.
Fort Worth, Texas 76134 USA
Printed in USA
©2006-2008 Alcon, Inc.
Revised: October 2007
PRINCIPAL DISPLAY PANEL
Omni pred ®
(prednisolone acetate ophthalmic suspension) 1%
| OMNIPRED |
prednisolone acetate suspension
|Labeler — Alcon Laboratories, Inc. (008018525)|
Revised: 06/2020 Alcon Laboratories, Inc.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.